Environmental Exposure to Polychlorinated Biphenyls and Placental CYP1A1 Activity in Inuit Women from Northern Québec

Daria Pereg,1,2 Éric Dewailly,2 Guy G. Poirier,1 and Pierre Ayotte2

1Département de Biologie Médicale, Faculté de Médecine, Université Laval et Unité de recherche en santé et environnement, Ste-Foy, Québec, Canada; 2Département de Médecine Sociale et Préventive, Faculté de Médecine, Université Laval et Unité de recherche en santé publique, Beauport, Québec, Canada

Some polychlorinated biphenyl (PCB) congeners are CYP1A1 inducers, and induction of this enzyme in the placenta has been linked to adverse effects on fetal development. The objective of this study was to determine if the body burden of PCBs is related to placental CYP1A1 activity in Inuit women from Nunavik (northern Quebec), a population highly exposed to organochlorines. Placenta and cord blood samples were obtained from 35 Inuit women and 30 women from a southern Quebec community exposed to background levels of organochlorines. We measured PCB concentrations in all cord plasma samples and in a subset of placenta samples from the Nunavik group and assessed CYP1A1 activity (ethoxyresorufin-O-deethylase; EROD) in placental microsomes from all participants. Concentrations of PCBs in cord plasma were strongly correlated to those in placenta (Pearson’s r = 0.77–0.97, p < 0.001) and were on average 4-fold higher in Inuit women than in southern Quebec women [for PCB 153, the geometric means (geometric SDs) were 83.3 (1.9) ng/g lipid vs. 16.9 (1.6) ng/g lipid, respectively]. Despite this difference in PCB body burden, both study groups had similar EROD activities when data were stratified according to tobacco smoking. Although simple correlation analysis first showed that placental EROD activity was correlated with PCB 153 plasma concentration in the Nunavik group, a multivariate analysis failed to demonstrate a significant contribution of PCBs to EROD activity when tobacco smoking was included in the analysis. We conclude that dietary exposure to PCBs in Inuit women from Nunavik does not significantly influence EROD activity in the placenta, implicating tobacco smoking as the major modulating factor.

Key words: CYP1A1, Inuit, placenta, polychlorinated biphenyl, tobacco smoke. Environ Health Perspect 110:607–612 (2002). [Online 29 April 2002]

http://ehpnet1.niehs.nih.gov/docs/2002/110p607-612pereg/abstract.html

Polychlorinated biphenyls (PCBs) are synthetic compounds containing a biphenyl moiety substituted with 1–10 chloride atoms (209 possible congeners). PCBs were synthesized and sold as congener mixtures characterized by their chlorine content (1). Their chemical and thermal stability made them suitable for diverse industrial applications, but their resistance to metabolic degradation contributed to their persistence in the environment and their biomagnification in food chains all over the world. Despite the ban on production, sale, and import of PCBs into North America since 1978, animal and human populations are still being exposed to these compounds (2,3), even in areas far away from industrial sources, due to long-range atmospheric and oceanic transport (4,5).

Prenatal exposure to PCBs has been linked to adverse developmental effects in human populations exposed accidentally (6–10), occupationally (11), and environmentally (12–19) to these compounds. The underlying mechanisms of these toxic effects have not been fully elucidated, but several lines of evidence suggest that the mechanism may involve altered signaling in pathways modulated by the aryl hydrocarbon receptor (AhR) (20,21). AhR ligands include polycyclic aromatic hydrocarbons (PAHs), polychlorodibenzop-dioxins (PCDDs), polychlorodibenzofurans (PCDFs), coplanar PCBs [International Union of Pure and Applied Chemistry (IUPAC) numbers, 77, 81, 126, and 169], and mono-ortho-substituted PCBs (PCBs 105, 114, 118, 123, 156, 157, 189) (22,23). Binding of these compounds to the AhR activates the receptor, which in turn binds to DNA and regulates the expression of several genes (potentially mediating toxicity), including cytochrome P450 1A1 (CYP1A1) (24,25).

CYP1A1 induction was previously used as a biomarker of environmental exposure to AhR agonists (mostly PAHs) in animal (26) and human (27,28) populations. Placental CYP1A1 induction was also reported in women who smoked during pregnancy (29–32). In addition, CYP1A1 induction was suggested as a biomarker of adverse developmental effects. In a study by Pelkonen et al. (33), newborns from smokers with high placental aryl hydrocarbon hydroxylase (AHH) activity (CYP1A1-related) had lower birth weights than newborns from smokers with lower placental AHH activity. CYP1A1 activity (AHH) was also 100-fold higher in Taiwanese women with Yu-Cheng syndrome (which resulted from high-level exposure to PCBs and their degradation by-products, such as PCDFs) than in Taiwanese and American women exposed to background levels of these compounds (6). Placental CYP1A1 activity (AHH) in Taiwanese women with Yu-Cheng syndrome was also about 10-fold higher than in American women exposed to background levels of organochlorines who smoked during pregnancy (6). In addition, an inverse correlation of ethoxyresorufin-O-deethylase (EROD) and AHH enzyme activities to birth weight was subsequently reported in Yu-Cheng patients (34). These results indicated that accidental exposure to PCBs and PCDFs induced placental CYP1A1 activity and further suggested a relation between placental CYP1A1 activity and adverse developmental effects. However, the effects of an environmental exposure to PCBs and other AhR agonists on placental CYP1A1 activity has yet to be investigated in populations exposed through dietary intake.

The Inuit population of Nunavik (northern Quebec, Canada) is exposed to unusually high doses of PCBs and other organochlorines due to their consumption of a traditional diet that includes large quantities of sea mammal fat (35–40). Concentrations of PCBs in breast milk were 5-fold greater in the Nunavik population than in populations from southern Quebec (41). The difference between plasma concentrations of dioxin-like compounds in Inuit adults and southern Quebec adults was even more pronounced (184 ng toxic equivalents (TEQ)/kg lipid vs. 26 ng TEQ/kg lipid), and TEQs were mostly accounted for by PCBs in the Inuit population (35). The present investigation was part of a cohort study addressing child development in Nunavik Inuit. The objective was to investigate the distribution of PCBs in the...
fetal–placental unit and the relationship between PCB exposure and CYP1A1 activity in placental tissue from Inuit women in Nunavik. Tobacco smoking during pregnancy was assessed because of its potential confounding effect on CYP1A1 induction.

**Materials and Methods**

**Population description and sampling.** Thirty-five Inuit women residing in Nunavik were recruited upon entering Kuujjuaq hospital to give birth. Thirty white women were also recruited in a southern Québec population (Sept-Iles) exposed to background levels of organochlorines (42). After thorough explanation of the project and after signing a consent form, women answered a questionnaire addressing smoking and dietary habits and gave their consent to placental and umbilical cord blood sampling. The southern Québec group comprised 15 smokers and 15 non-smokers; the Nunavik group comprised 23 smokers and 12 nonsmokers (based on self-declared cigarette smoking during pregnancy) (42). Maternal smoking status was ascertained using cotinine content in meconium (32,43) in order to adequately control for the potential confounding effect of tobacco smoke-related placental CYP1A1 induction (29–33).

Umbilical cord blood samples (30 mL) were collected in vacutainers containing EDTA as the anticoagulant and centrifuged, and the plasma was transferred to glass vials prewashed with hexane. Plasma samples were stored at −20°C until analysis. Placentas were collected within 1 hr after delivery. Connective tissue and blood vessels were removed, and then 10-g samples were cut and frozen at −80°C in polycarbonate vials until they were shipped to the laboratory on tillied water, and potassium hydroxide and concentrated under vacuum. The extracts were then purified by chromatography on acidified silica gel and Florisil columns. Fourteen PCB congeners (PCBs 28, 52, 99, 101, 105, 118, 128, 138, 153, 156, 170, 180, 183, 187) were measured in the plasma and placenta extracts by high-resolution gas chromatography with electron capture detection. PCB analyses were carried out using an HP-5890 series II gas chromatograph equipped with dual-capillary columns (Ultra-1 and Ultra-2, Hewlett Packard, Palo Alto, CA, USA) and dual Ni-63 electron-capture detectors (Hewlett Packard). Using a computer program developed in-house, we identified peaks by their relative retention times obtained on the two columns.

Total cholesterol, free cholesterol, and triglycerides were measured in plasma samples by standard enzymatic procedures, and phospholipids were determined according to the enzymatic method of Takayama et al. (49), using a commercial kit (Wako Pure Chemical Industries, Richmond, VA). We estimated the concentration of total plasma lipids according to the formula developed by Phillips et al. (46).

**Analyses of PCBs in plasma and placenta samples.** We measured PCBs in all umbilical cord plasma samples from both groups and in a subset of placental samples from the Nunavik group (n = 20). Extraction of plasma samples (2 mL) was carried out with ammonium sulfate:ethanol:hexane (1:1:3). Extracts were concentrated and purified by chromatography on Florisil columns. Lipids were extracted from placental tissue with acetone:hexane (2:1). An aliquot of the organic fraction was evaporated to constant weight for the gravimetric determination of the lipid content. The remaining organic fraction was washed with concentrated sulfuric acid, distilled water, and potassium hydroxide and concentrated under vacuum. The extracts were then purified by chromatography on acidified silica gel and Florisil columns. Fourteen PCB congeners (PCBs 28, 52, 99, 101, 105, 118, 128, 138, 153, 156, 170, 180, 183, 187) were measured in the plasma and placenta extracts by high-resolution gas chromatography with electron capture detection. PCB analyses were carried out using an HP-5890 series II gas chromatograph equipped with dual-capillary columns (Ultra-1 and Ultra-2, Hewlett Packard, Palo Alto, CA, USA) and dual Ni-63 electron-capture detectors (Hewlett Packard). Using a computer program developed in-house, we identified peaks by their relative retention times obtained on the two columns.

**Cotinine determination in meconium.** We extracted cotinine from meconium according to the procedure developed by Lewis (44). Meconium samples were homogenized in glacial acetic acid and acetone/diphenylamine solution (1:2). The solvents were evaporated and the residue dissolved in phosphate buffer (60 mM, pH 6.0). Cotinine was extracted by solid-phase extraction and measured by mass spectrometry. The detection limit for cotinine in meconium was 5 ng/g dry weight, and the coefficient of variation was 8.8% (based on seven analyses of the same sample).

**Average recoveries varied from 95% to 122% in spiked samples.** We reassigned participants to the appropriate smoking category (nonsmokers, moderate, and heavy smokers) based on the cotinine content of meconium samples and on cut-off values determined previously (< 5 ng/g, 5 to < 86 ng/g, ≥ 86 ng/g) (32).

**Table 2.** PCB concentrations (ng/g plasma lipids) in umbilical cord plasma from southern Québec and Nunavik groups.

| Congener | CI position | Southern Québec (n = 30) | Nunavik (n = 35) |
|----------|-------------|-------------------------|-----------------|
|          |             | GM (GSD)² | Percent detected | GM (GSD) | Percent detected |
| PCB 28   | 2,4,4’      | < LOD²   | 6.7            | < LOD    | 0 |
| PCB 52   | 2,2,5,5’    | < LOD    | 30             | < LOD    | 43 |
| PCB 99   | 2,2,4,4,5   | 5.7 (1.5) | 50             | 18.9 (1.8) | 97 |
| PCB 101  | 2,2,4,5,5   | 9.7 (2.1) | 63             | 7.7 (1.9)  | 63 |
| PCB 105  | 2,3,4,4,4   | < LOD    | 3.3            | < LOD    | 20 |
| PCB 118  | 2,3,4,4,5   | < LOD    | 40             | 16.7 (1.8) | 97 |
| PCB 128  | 2,2,3,3,4,4 | < LOD    | —              | < LOD    | 0 |
| PCB 138  | 2,3,3,4,4,5 | 12.7 (1.6)| 93             | 58.4 (1.9* | 100 |
| PCB 153  | 2,2,4,5,5   | 16.9 (1.6)| 97             | 83.3 (1.9* | 100 |
| PCB 156  | 2,3,4,4,5   | < LOD    | —              | < LOD    | 40 |
| PCB 170  | 2,3,4,4,5,5 | < LOD    | 10             | 10.4 (2.3) | 71 |
| PCB 180  | 2,3,4,4,5,5 | 7.2 (1.6)| 67             | 31.8 (2.0) | 100 |
| PCB 183  | 2,3,4,4,5,6 | < LOD    | 13             | 6.5 (1.6)  | 51 |
| PCB 187  | 2,3,4,5,5,6 | < LOD    | 17             | 18.4 (1.8) | 97 |

*aCalculated for congeners detected in > 50% of samples. bMean value below the limit of detection (LOD); range, 5–8 ng/g plasma lipids. p < 0.001; Student’s t-tests conducted for congeners detected in > 70% of samples.

**Table 1.** Characteristics of participants.

| Characteristic | Percent | Southern Québec | Nunavik | p-Value |
|----------------|---------|-----------------|---------|---------|
|                | Mean¹ | SD  | No. | Mean¹ | SD  | No. |
| Maternal Age (year) | 25.9 | 5.2 | 30 | —    | —   | 35 | 0.264 |
| Weight before pregnancy (kg) | — | 59.7 | 11.6 | — | 59.8 | 13.6 | 25 | 0.980 |
| Smoked during pregnancy (%) | 50.0 | — | 30 | — | 65.7 | — | 35 | 0.219 |
| Cigarettes per day during pregnancy | 11.7 | 6.6 | 15 | — | 12.6 | 9.2 | 23 | 0.742 |
| Parity (percent primiparous) | 36.6 | — | 30 | 11.4 | — | 35 | 0.020 |
| Newborn Male (%) | 46.6 | — | 30 | 34.2 | — | 35 | 0.325 |
| Weight (kg) | — | 3.33 | 0.49 | 30 | — | 3.44 | 0.44 | 33 | 0.343 |
| Length (cm) | — | 50.9 | 2.1 | 30 | — | 50.1 | 2.4 | 33 | 0.737 |

¹Arithmetic mean, ²p-Value for Student’s t-test (comparison of means) or Fisher’s exact test (comparison of proportions). *Among smokers; one nonsmoker in each group reported smoking before pregnancy (five cigarettes/day).
Quality control was performed using the SRM-1588 standard (National Institute of Standards and Technology, Gaithersburg, MD, USA). In placental samples, percent recovery ranged between 74% and 106% for all PCB congeners (n = 3). The detection limit for PCB congeners ranged between 2.3 and 4.1 ng/g lipids. Coefficients of variation were between 9.1% and 29.9%, and biases ranged from –23.4% to +5.6%, based on 20 determinations. In plasma samples, percent recoveries were > 92%, and the detection limit was 0.02 µg/L for all congeners. Coefficients of variation ranged from 2.1% to 7.5%, and bias ranged from –10.9% to +3.0%. PCB analyses were carried out by the laboratory of the Institut National de Santé Publique du Québec, which is accredited by the Canadian Association for Environmental Analytical Laboratories.

**Determination of CYP1A1 enzyme activity.** Microsomal fractions were isolated from placental tissue by differential centrifugation and stored in Tris-sucrose buffer (50 mM Tris-0.25 M sucrose, pH 8.0) at –80°C until further processing. We assayed EROD activity in 96-well plates with simultaneous protein quantification using fluorescamine labeling, according to a modification of a method described previously (47,48). Each sample was analyzed in quadruplicate (2 x 25 µL and 2 x 10 µL microsomes) and assayed on different plates. We used microsomes from cells expressing CYP1A1 (Gentest Corp., Woburn, MA, USA) as positive controls, and analyzed six blank wells on each plate to determine the detection limit of resorufin and fluorescamine fluorescence. We always performed a dual standard curve of bovine serum albumin and resorufin on each plate. EROD activity was expressed in picomoles of resorufin formed per minute per milligram of microsomal proteins.

**Statistical analyses.** PCB plasma concentrations and EROD activity did not follow a normal distribution, and these variables were normalized through a logarithmic conversion \((\log_{10})\) before further processing. A value equal to one-half the detection limit was attributed to samples below the detection limit. We calculated geometric means (GMs) and standard deviations (GSDs) for congeners detected in > 50% of samples. Statistical testing was conducted for congeners detected in > 70% of samples. We compared means using Student’s \(t\)-tests and compared proportions by Fisher’s Exact tests. Correlations between concentrations of PCBs were tested using Pearson correlation coefficients, whereas Spearman correlation coefficients were used to test correlations involving cotinine concentration in meconium. Analyses of variance or covariance were carried out to test the effect of PCB exposure and smoking on EROD activity. For all analyses, the level of significance \((\alpha)\) was 0.05. All statistical tests were performed using the SPSS 8.0 for Windows statistical package (SPSS Inc., Chicago, IL, USA).

**Results**

Among all maternal and newborn characteristics listed in Table 1, only parity differed between groups. There were fewer primiparous women in the Inuit group than in the southern Québec group \((p = 0.02)\). Birth weight was similar in both groups, but when data were stratified by smoking status, mean birth weight of newborns from smokers was lower than that from nonsmokers by an average of 359 g in the southern Québec group \((p = 0.04)\) and 272 g in the Nunavik group \((p = 0.16)\).

Most PCB congeners were detected more frequently in plasma samples from the Nunavik group than in those from the southern Québec group (Table 2). PCB 138 and PCB 153 were detected in > 90% of samples in both groups, and their plasma concentrations were on average 4-fold higher in the Nunavik group than in the southern Québec group. Other congeners detected in > 50% of samples in the Nunavik group were PCBs 99, 101, 118, 170, 180, 183, and 187.

PCB analyses in placental samples from the Nunavik group \((n = 20)\) revealed lower concentrations in placenta than in umbilical
cord plasma. This observation was particularly striking for highly persistent congeners 138, 153, and 180, as well as for mono-ortho-substituted congener 118, which were all 1.5- to 2-fold lower in placenta than in umbilical cord plasma (Figure 1). PCB concentrations in placenta were highly correlated with those in umbilical cord plasma, and correlation coefficients ranged from 0.77 to 0.97 ($p < 0.001$) for all congeners detected in > 70% of samples (Table 3). Figure 2 illustrates the correlation for PCB 153. Correlations among PCB congeners detected in > 70% of umbilical cord plasma samples from Nunavik are shown in Table 4. PCB concentrations were strongly intercorrelated (Pearson’s $r > 0.75$, $p < 0.001$). In particular, the highly persistent congener PCB 153 was strongly correlated with other frequently detected PCB congeners in the Nunavik group, including PCB 118, a known AhR agonist. Hence PCB 153 is a good predictor of all major PCB congeners found in umbilical cord plasma samples from the Nunavik group. Furthermore, in view of the strong correlation noted above between PCB 153 concentrations in plasma and placenta (Figure 2), we selected PCB 153 concentration in umbilical cord plasma as the exposure variable in further statistical analyses involving placental biomarkers.

We assessed CYP1A1 activity (EROD) in placental microsomes. EROD activity levels (GM [GSD]) in the southern Quebec and Nunavik groups were 6.1 (3.6) and 4.6 (3.6) pmol resorufin/min/mg protein, respectively. A statistically significant correlation of placental EROD activity to PCB 153 plasma concentration was observed in the Nunavik group (Pearson’s $r = 0.38$, $p = 0.02$), but not in the southern Quebec group ($p = 0.69$). Placental EROD activity was also significantly correlated with cotinine concentration in meconium in the Nunavik group (Spearman’s $r = 0.80$, $p < 0.001$), as well as in the southern Quebec group ($r = 0.78$, $p < 0.001$).

Table 5 shows the number of participants in each smoking category before and after recategorization based on the concentration of cotinine in meconium samples. Several women from both groups were reclassified in appropriate smoking categories based on cutoff values determined previously (32). Figure 3 presents EROD activities in both groups according to these smoking categories. The mean value in moderate smokers was approximately 2-fold greater than that of nonsmokers. EROD activities in heavy smokers were further increased by a factor of four compared to those of moderate smokers.

A two-way analysis of variance ($R^2 = 0.56$, $p < 0.001$) showed that EROD activity was related to smoking status during pregnancy ($p < 0.001$), but not to the study group to which women belonged ($p = 0.42$), suggesting that smoking was the main determinant of EROD activity variation. An analysis of covariance carried out in the Nunavik group only ($R^2 = 0.52$, $p < 0.001$) revealed that the relation initially found between placental EROD activity and PCB 153 in simple correlation analysis was no longer statistically significant when tobacco smoke exposure was accounted for, and that the latter explained most of the variability in EROD activity ($p < 0.001$). Further analyses showed that the mean PCB 153 plasma concentration in smokers was greater than that in nonsmokers of the Nunavik group (mean difference $= 1.28$ ng/g lipids, $p = 0.01$). Furthermore, cotinine concentration in meconium was correlated with PCB 153 plasma concentration (Spearman’s $r = 0.42$, $p = 0.011$) in this group. Smoking was not related to PCB 153 plasma concentration in the southern Quebec group.

**Discussion**

The objective of the present study was to determine if placental CYP1A1 activity, a potential marker of adverse developmental effects, was related to dietary PCB exposure in the Inuit population of Nunavik. The potential confounding effect of tobacco smoking was accounted for in the analysis because it is known to modulate placental CYP1A1 activity. Our results demonstrate that PCB body burden does not significantly influence placental CYP1A1 activity, implicating smoking during pregnancy as the major modulating factor.

Placental CYP1A1 induction has been previously reported in women who smoked during pregnancy (30,31,49) and further related to lower birth weight (33). In the present study, the Nunavik and the reference groups were similar with regard to several maternal and newborn characteristics. Smoking is more prevalent in the Nunavik population than elsewhere in Quebec (50), a situation that made rigorous matching for smoking status nearly impossible. However, oversampling of smokers in the southern Quebec group and of nonsmokers in the Nunavik group was performed to reach a balanced study design, thereby allowing us to test the effect of PCBs on CYP1A1 activity while controlling for the effect of tobacco smoking. Smoking status was further ascertained by the use of cotinine concentration in meconium, a biomarker previously validated (32), which led to the reclassification of several participants in the appropriate smoking category. This emphasizes the potential misclassification bias that may be induced by relying only on self-declared cigarette consumption to determine smoking status during pregnancy.

Body burden of PCBs observed in the Nunavik study group, as assessed by umbilical cord plasma concentrations expressed on a lipid basis, was consistent with that documented in earlier reports (35,41), with concentrations of major PCB congeners being approximately 4-fold higher in the Nunavik group than in the southern Quebec group. Strong CYP1A1 inducers such as coplanar PCBs (PCBs 77, 126, and 169) and PCDDs/PCDFs could not be measured in the present study due to the high volume of umbilical cord plasma needed to conduct these analyses.

**Table 4. Pearson’s correlation coefficients between concentrations of various PCB congeners in umbilical cord plasma from Nunavik neonates.**

| PCB | PCB 99 | PCB 118 | PCB 138 | PCB 153 | PCB 170 | PCB 180 | PCB 183 |
|-----|--------|--------|--------|--------|--------|--------|--------|
| PCB 99 | - | 0.92 | - | - | - | - | - |
| PCB 118 | 0.92 | - | 0.98 | - | - | - | - |
| PCB 138 | 0.92 | 0.98 | - | 0.99 | - | - | - |
| PCB 153 | 0.90 | 0.85 | 0.99 | - | - | - | - |
| PCB 170 | 0.79 | 0.74 | 0.93 | 0.94 | - | - | - |
| PCB 180 | 0.82 | 0.78 | 0.95 | 0.97 | 0.97 | - | - |
| PCB 183 | 0.77 | 0.76 | 0.81 | 0.79 | 0.77 | 0.80 | - |
| PCB 187 | 0.83 | 0.82 | 0.94 | 0.95 | 0.93 | 0.96 | 0.81 |

*Pearson’s $r$ were calculated for congeners detected in > 70% of plasma and placental samples. All correlation coefficients were statistically significant ($p < 0.001$).

**Table 5. Classification of participants in smoking categories based on self-declared cigarette smoking and after reclassification based on cotinine concentration in meconium.**

| Self-declared smoking (cigarettes/day) | Southern Québec (n) | Nunavik (n) |
|--------------------------------------|---------------------|-------------|
| Nonsmokers (0)                       | 15                  | 12          |
| Moderate smokers (1–10)              | 6                   | 11          |
| Heavy smokers (> 10)                 | 9                   | 12          |
| Total                                | 30                  | 35          |
| After reclassification (cotinine, ng/g) |                     |
| Nonsmokers (ND)                      | 15                  | 8           |
| Moderate smokers (< 66)              | 6                   | 10          |
| Heavy smokers (≥ 66)                 | 9                   | 17          |
| Total                                | 30                  | 35          |

ND, not detected.
Environmental Health Perspectives • VOLUME 110 | NUMBER 6 | June 2002

Environmental Health Criteria 140. Geneva:WHO Health Organization, 1993.

Barrie LA, Greger D, Hargrave B, Lake R, Muir D, Shearer R, Tracey B, Bifetman T. Arctic contaminants: sources, occurrence and pathways. Sci Total Environ 121–122:74 (1992).

MacDonald RW, Barrie LA, Bifetman TF, Diamond ML, Greger DJ, Semkin RG, Wang F, Alase M, et al. Contaminants in the Canadian Arctic 5 years of progress in understanding sources, occurrence and pathways. Sci Total Environ 254/255:294 (2000).

Wong TK, Eversson RB, Hsu ST. Potential induction of human placental mono-oxygenase activity by previous dietary exposure to polychlorinated biphenyls and their thermal degradation products. Lancet 1:721–724 (1985).

Rogan WJ, Gladen BC, Hung KL, Kalaj LA, Shiib LY, Taylor JS, Wu YC, Yang D, Ragan NB, Hsu CC. Congenital poisoning by polychlorinated biphenyls and their contaminants in Taiwan. Science 214:338–339 (1981).

Chen YJL, Guo YL, Hsu CC, Ragan WJ. Cognitive development of Yu-Cheng (I Oil Disease) children prenatally exposed to heat-degraded PCBs. JAMA 268:3213–3218 (1992).

Guo YL, Lambert GH, Hsu C-C. Growth abnormalities in the population exposed in utero and early postnatally to polychlorinated biphenyls and dibenzofurans. Environ Health Perspect 103(suppl 6):117–122 (1995).

Guo YL, Yu ML, Hsu C-C, Ragan WJ. Chloracne, goiter, arthrosis, and anemia after polychlorinated biphenyl poisoning: 14-year follow-up of the Tainan Yucheng cohort. Environ Health Perspect 107:715–719 (1999).

Taylor PR, Stolma JM, Lawrence CE. The induction of polychlorinated biphenyls to birth weight and gestational age in the offspring of occupationally exposed mothers. Am J Epidemiol 129:395–408 (1989).

Rylander L, Strömberg LJ, Hagar L. Decreased birthweight among infants born to women with a high dietary intake of fish contaminated with persistent organochlorine compounds. Scand J Work Environ Health 21:388–395 (1995).

Rylander L, Strömberg U, Dyremark E, Östman C, Nilsson-Ehle P, Hagar L. Polychlorinated biphenyls in blood plasma among Swedish female fish consumers in relation to low birth weight. Am J Epidemiol 147:493–502 (1998).

Fein GG, Jacobsen JL, Jacobson SW, Schwartz PM, Dowler JK. Prenatal exposure to polychlorinated biphenyls: effects on birth size and gestational age. J Pediatr 105:315–320 (1984).

Patandin S, Koopman-esseboe C, de Riddere MA, Weislags-Kuperus N, Sauer P. Effects of environmental exposure to polychlorinated biphenyls and dioxins on birth size and growth in Dutch children. Pediatr Res 44:538–545 (1998).

Gladen BC, Ragan WJ, Hardy P, Thullen J, Tinglestad J, Tully M. Development after exposure to polychlorinated biphenyls and dioxins: long-term transgenerational and through human milk. J Pediatr 113:991–995 (1988).

Rogan WJ, Gladen BC, PCBs, and child development at 18 and 24 months. Am J Epidemiol 140:417–433 (1999).

Rogan WJ, Jacobson SW. Evidence for PCBs as neurodevelopmental toxicants in humans. Neurotoxiology 18:415–424 (1997).

Jacobson JL, Jacobson SW. Intellectual impairment in children exposed to polychlorinated biphenyl in utero. N Engl J Med 335:763–769 (1996).

Safe SH. Polychlorinated biphenyls (PCBs): environmental impact, biochemical and toxic responses, and implications for risk assessment. Crit Rev Toxicol 24:87–149 (1994).

Giesy JP, Kannan K. Dioxin-like and non-dioxin-like toxic effects of polychlorinated biphenyls (PCBs): implications for risk assessment. Crit Rev Toxicol 28:511–569 (1998).

Okey AB. Enzyme induction in the cytochrome P-450 system. Pharmacol Ther 45:241–298 (1990).

Van den Berg M, Binnumb L, Busveld ATC, Bruinstorm C, Broek J, Featley M, Siesy JP, Hanberg A, Hasegawa R, Kennedy SW, et al. Toxic equivalency factors (TEFs) for PCBs, PCDDs, PCDFs for humans and wildlife. Environ Health Perspect 106:775–792 (1998).

Denison MS, Whisstock JP. Xenobiotic-inducible transcription of cytochrome P450 genes. J Biol Chem 270:18175–18178 (1995).

Safe S, Krishnan V. Cellular and molecular biology of aryl hydrocarbon (AH) receptor-mediated gene expression. Arch Toxicol Suppl 17:99–115 (1995).
26. Stegeman JJ, Brouwer M, Di Giulio RT, Forlin L, Fowler BA, Sanders EM, Van Veld PA. Enzyme and protein synthesis as indicators of contaminant exposure and effect. In: Biomarkers: Biochemical, Physiological and Histological Markers of Anthropogenic Stress (Huggett RJ, Kimerle RA, Mehrie PM, Bergman HL, eds). Boca Raton, FL: Lewis Publishers, 1992:335–338.

27. Vandeven Heuvel JP, Clark GC, Thompson CI, McCoy Z, Miller CR, Lucier GW, Bell DA. CYP1A1 mRNA levels as a human exposure biomarker: use of quantitative polymerase chain reaction to measure CYP1A1 expression in human peripheral blood lymphocytes. Carcinogenesis 14:2003–2006 (1993).

28. Whyatt RM, Garte SJ, Cosma G, Bell DA, Jedrychowski W, Wahrenrod J, Randall MC, Cooper TB, Ottman R, Tang D, et al. CYP1A1 messenger RNA levels in placental tissue as a biomarker of environmental exposure. Cancer Epidemiol Biomarkers Prev 4:147–153 (1995).

29. Huel G, Girard F, Nessmann C, Godin J, Blot P, Breart G, Moreau T. Placental aryl hydrocarbon hydroxylase activity and placental calcifications. Toxicology 71:257–266 (1992).

30. Boden AG, Bush PD, Burke MD, Abramovich DR, Aggett P, Mayhew TM, Page KR. Human placental cytochrome P450 and quinone reductase enzyme induction in relation to maternal smoking. Reprod Fertil Dev 7:1521–1524 (1995).

31. Manchester DK, Jacoby EH. Sensitivity of human placental monooxygenase activity to maternal smoking. Clin Pharmacol Ther 30:682–692 (1981).

32. Pereg D, Lagueux J, Poirier GG, Ayotte P. Cigarette smoking during pregnancy: comparison of biomarkers for inclusion in epidemiological studies. Biomarkers 6:161–173 (2001).

33. Pelkonen O, Kärki NT, Koivisto M, Tuimala R, Kauppila A. Maternal cigarette smoking, placental aryl hydrocarbon hydroxylase and neonatal size. Toxicol Lett 3:331–335 (1979).

34. Lucier GW, Nelson KG, Everson RB, Wong TK, Phlipot RM, Tierani T, Taylor M, Sunahara GL. Placental markers of human exposure to polychlorinated biphenyls and polychlorinated dibenzofurans. Environ Health Perspect 76:79–87 (1987).

35. Ayotte P, Dewailly E, Ryan JJ, Bruneau S, Lebel G. PCBs and dioxin-like compounds in plasma of adult Inuit living in Nunavik (Arctic Quebec). Chemosphere 34:1459–1468 (1997).

36. Dewailly É, Ayotte P, Bruneau S, Laliberté C, Muir DCS, Norstrom RJ. Inuit exposure to organochlorines through the aquatic food chain in Arctic Québec. Environ Health Perspect 101:618–620 (1993).